CU6

6.25%

$4.25

CLARITY PHARMACEUTICALS LTD

Market Cap $1.363B Add to my watchlist

Healthcare Biotechnology

Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical... Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. It is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. It has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. WEBINAR: What investors should know about what it takes for ASX-listed companies to get medical developments...

Latest Threads

Tag

Subject

CU6

What the F?

12:12

5.6K

12:12

Last post GreatMinds

5.6K

CU6

CU6 - Media and Industry News

10 11 12

26/12/24

708

298K

26/12/24

Last post ttppxx

708

298K

CU6

CU6 - ASX Charts

23 24 25

26/12/24

1.4K

555K

26/12/24

Last post Vivo

1.4K

555K

CU6

The Bear Room

3 4 5

24/12/24

246

106K

24/12/24

Last post santo.nath

246

106K

CU6

Ann: Novel FAP-targeted radiopharmaceutical

23/12/24

13K

23/12/24

Last post ttppxx

13K

CU6

Ann: Cleansing Notice

18/12/24

349

18/12/24

Last post

ASX News

349

CU6

Ann: Application for quotation of securities - CU6

18/12/24

311

18/12/24

Last post

ASX News

311

CU6

Ann: S&P DJI Announces December 2024 Quarterly Rebalance

12/12/24

10K

12/12/24

Last post ttppxx

10K

See All Discussions

Timeline

Cleansing Notice
18 Dec 16:01	Share

Application for quotation of securities - CU6
18 Dec 15:53	Share

Novel FAP-targeted radiopharmaceutical
18 Dec 09:57	Share

S&P DJI Announces December 2024 Quarterly Rebalance
06 Dec 17:08	Share

Cleansing Notice
06 Dec 08:57	Share

Application for quotation of securities - CU6
06 Dec 08:56	Share

Last patient assessment completed for SARTATE trial
28 Nov 09:57	Share

First 2 participants dosed with Cu-64 SAR-bisPSMA in Co-PSMA
26 Nov 09:56	Share

Change of Director's Interests - All Directors
26 Nov 09:31	Share

Notification regarding unquoted securities - CU6
25 Nov 14:34	Share

Results of Meeting
20 Nov 13:27	Share

Chairperson Address AGM
20 Nov 09:27	Share

AGM MD Presentation
20 Nov 09:25	Share

Head-to-head IIT with SAR-bisPSMA
18 Nov 09:36	Share

Clarity and Nucleus RadioPharma sign MSA
11 Nov 09:37	Share

CMS final rule on radio-diagnostic reimbursement policy
05 Nov 09:50	Share

Notification regarding unquoted securities - CU6
01 Nov 10:41	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Oct 14:18	Share

Cleansing Notice
28 Oct 14:34	Share

Application for quotation of securities - CU6
28 Oct 14:32	Share

Notice of Annual General Meeting/Proxy Form
18 Oct 10:50	Share

Cleansing Notice
17 Oct 09:55	Share

Application for quotation of securities - CU6
17 Oct 09:50	Share

Copper-67 SAR-bisPSMA updates
16 Oct 09:33	Share

Positive guidance from the US FDA on Phase III trial
14 Oct 09:49	Share

Michelle Parker Promoted to CEO
14 Oct 09:45	Share

Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA
08 Oct 09:52	Share

Change of Director's Interest Notices - AT CB CR TR MP
04 Oct 08:42	Share

Cleansing Notice
02 Oct 18:43	Share

Application for quotation of securities - CU6
02 Oct 18:39	Share

View More

(20min delay)
Last $4.25		Change 0.250(6.25%)		Mkt cap ! $1.363B

Open	High	Low	Value	Volume
$4.04	$4.25	$4.04	$6.228M	1.493M

Buyers (Bids)

No.	Vol.	Price($)
1	25000	$4.21

Sellers (Offers)

Price($)	Vol.	No.
$4.25	7933	2

View Market Depth

No.	Vol.	Price($)
1	1000	4.180
1	5000	4.170
1	1515	4.160
1	2960	4.150
1	3000	4.140

Price($)	Vol.	No.
4.250	7933	2
4.260	700	1
4.350	2500	1
4.440	600	1
4.450	87	1

Last trade - 16.10pm 27/12/2024 (20 minute delay)

CU6 (ASX) Chart

CLARITY PHARMACEUTICALS LTD

Latest Threads

Timeline

Featured News

Latest Videos

Clarity Pharmaceuticals' (ASX:CU6) theranostic prostate cancer trial progresses to highest dose level

10 Aug 2023 12:13 (AEST)

Latest Articles

Clarity progresses SECuRE trial with positive safety results

Clarity Pharmaceuticals Ltd has reported strong results from Cohort 4 of the SECuRE trial examining a treatment for prostate cancer

US FDA awards Clarity Pharma's novel prostate cancer PET scan imaging compound fast track status

Clarity Pharmaceuticals (ASX:CU6) has revealed it's received fast track status from the US FDA for its prostate cancer imaging compound designed for PET scans.

Clarity Pharmaceuticals achieves recruitment target for phase II SAR-Bombesin prostate cancer trial

Clarity Pharmaceuticals (ASX:CU6) has imaged 50 patients with Cu-SAR-Bombesin in its United States-based diagnostic trial, SABRE.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News